|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-24
|
|
pubmed:abstractText |
SAR studies and optimization of various modified Hygromycin A fluoroalkyl ethers, which led to the discovery of the highly potent 4'-(2-cyclopropyl-2-fluoroethyl ether) antibacterial CE-156811 (1) derived from truncation of the ribose ring and difluorination of the phenyl found in Hygromycin A, are discussed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:BordnerJonJ,
pubmed-author:BricknerSteven JSJ,
pubmed-author:BrightyKatherineK,
pubmed-author:ConnollyAnn GAG,
pubmed-author:DuignanJoanJ,
pubmed-author:FineganSteveS,
pubmed-author:GirardDennisD,
pubmed-author:LePhuong TPT,
pubmed-author:LirasJenniferJ,
pubmed-author:MaloneyMeghanM,
pubmed-author:MonahanRhondaR,
pubmed-author:SamardjievIvanI,
pubmed-author:SchaferJohnJ,
pubmed-author:StoneGregory GGG,
pubmed-author:WadeSarah KSK,
pubmed-author:ZaniewskiRichard PRP
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
276-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21115249-Administration, Oral,
pubmed-meshheading:21115249-Animals,
pubmed-meshheading:21115249-Anti-Bacterial Agents,
pubmed-meshheading:21115249-Cinnamates,
pubmed-meshheading:21115249-Dioxoles,
pubmed-meshheading:21115249-Dogs,
pubmed-meshheading:21115249-Drug Evaluation, Preclinical,
pubmed-meshheading:21115249-Haplorhini,
pubmed-meshheading:21115249-Hygromycin B,
pubmed-meshheading:21115249-Mice,
pubmed-meshheading:21115249-Microbial Sensitivity Tests,
pubmed-meshheading:21115249-Rats,
pubmed-meshheading:21115249-Structure-Activity Relationship
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: a novel potent antibacterial analog derived from hygromycin A.
|
|
pubmed:affiliation |
Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc, La Jolla, CA 92121, United States. phuong.le@pfizer.com
|
|
pubmed:publicationType |
Journal Article
|
